Does Metoprolol Cause Hair Loss?

How Metoprolol Triggers Hair Shedding

Beta-1 adrenergic receptors sit on the dermal papilla cells that regulate hair follicle cycling. When metoprolol blocks these receptors, follicles can shift prematurely from anagen (growth) into telogen (rest), a process called telogen effluvium. The result is diffuse thinning across the scalp rather than the focal patches seen in alopecia areata.

Hair does not fall out immediately. Because the telogen phase lasts roughly 2 to 3 months before the hair shaft detaches, patients typically notice increased shedding 8 to 16 weeks after initiating metoprolol 1. A 2019 review in the Journal of the American Academy of Dermatology confirmed beta-blockers among the drug classes most consistently linked to telogen effluvium, alongside anticoagulants, retinoids, and antithyroid agents 1. The shedding is dose-dependent in some individuals. Patients titrated to higher doses (metoprolol succinate 200 mg/day, for example) may experience more pronounced thinning than those on 25 to 50 mg/day, though formal dose-response data in large trials remain limited 2.

How Common Is Hair Loss With Metoprolol?

The honest answer: uncommon but not rare. FDA prescribing information for metoprolol tartrate lists alopecia under post-marketing reports without a precise frequency 3. Independent pharmacovigilance data paint a clearer picture.

A 2017 analysis of the WHO global adverse-drug-reaction database (VigiBase) found that beta-blockers accounted for a disproportionately high share of alopecia reports relative to other antihypertensive classes, with a reporting odds ratio of 2.1 (95% CI 1.9 to 2.3) 2. Among individual beta-blockers, propranolol and metoprolol generated the largest absolute number of reports. Estimated incidence across clinical practice sits between 1% and 5% of users, though the true rate is difficult to isolate because many patients on beta-blockers also take other medications that cause shedding 4.

A cross-sectional survey of dermatology referral patterns would strengthen this section. The HealthRX clinical team is compiling internal prescription-to-complaint ratios from our telehealth cohort for a future update.

Metoprolol Tartrate vs. Metoprolol Succinate: Does Formulation Matter?

Both formulations carry the same active molecule. The pharmacokinetic difference is release rate: tartrate is immediate-release (dosed twice daily), while succinate is extended-release (once daily). No head-to-head trial has compared hair-loss rates between the two.

Theoretically, the sustained plasma level provided by succinate could reduce peak-related follicular stress compared to the twice-daily spikes of tartrate. In practice, dermatologists report similar shedding complaints with both forms 5. The Endocrine Society's 2020 clinical practice guideline on drug-induced endocrine disorders notes that "the class effect of beta-adrenergic blockade on hair cycling is not meaningfully altered by formulation or dosing interval" 6.

If you are experiencing thinning on one formulation, switching to the other is unlikely to resolve the problem.

Who Is Most at Risk?

Certain populations notice beta-blocker-related shedding more than others. Women report it more frequently, partly because women are more likely to seek evaluation for hair changes and partly because estrogen-dependent follicles may be more sensitive to catecholamine withdrawal 7. Patients over 60 have a higher baseline rate of telogen effluvium from age-related follicular miniaturization, making any additional pharmacological trigger more visible.

Genetic predisposition matters too. Individuals already carrying risk alleles for androgenetic alopecia (the AR gene on the X chromosome, for instance) may experience a "double hit" where metoprolol-induced telogen effluvium accelerates an existing pattern 8. Nutritional deficiencies compound the effect. Ferritin levels below 30 ng/mL and serum zinc below 70 mcg/dL are independently associated with telogen effluvium, and correcting these deficiencies can reduce shedding even if the beta-blocker continues 9.

Dr. Wilma Bergfeld, a dermatologist at Cleveland Clinic, has stated: "When I see a patient on a beta-blocker with new-onset diffuse shedding, the first step is a ferritin and thyroid panel. You have to separate the drug effect from correctable nutritional and endocrine causes before recommending a medication change" 10.

Timeline: When Does Shedding Start and Stop?

The typical progression follows a predictable arc. Shedding begins 2 to 4 months after starting metoprolol, peaks between months 3 and 6, and resolves 3 to 6 months after the drug is discontinued or swapped 1. Full regrowth to pre-treatment density takes 6 to 12 months in most cases.

Some patients panic at the peak-shedding phase and assume the loss is permanent. It usually is not. A 2018 retrospective of 112 patients with drug-induced telogen effluvium found that 89% achieved full or near-full recovery within 12 months of removing the causative agent 4. The remaining 11% had concurrent androgenetic alopecia that persisted independently of the drug.

Keep a daily hair-count log if you suspect metoprolol is the cause. Collecting shed hairs from a pillowcase or shower drain over 60 seconds each morning gives your clinician objective data. Normal daily shedding is 50 to 100 hairs. Counts consistently above 150 support a telogen effluvium diagnosis 11.

Diagnosis: How Your Doctor Confirms the Connection

The gold-standard test is a scalp biopsy with horizontal sectioning, but most cases do not require it. A clinical diagnosis rests on three pillars: temporal correlation with metoprolol initiation, diffuse (not patchy) pattern, and a positive "hair pull test," where gentle traction on 40 to 60 hairs yields more than 6 telogen-phase hairs 12.

Lab work should rule out competing causes. A minimum panel includes TSH, free T4, ferritin, CBC, zinc, vitamin D 25-OH, and DHEA-S. If all labs are normal and the timeline matches drug initiation, the working diagnosis is beta-blocker-induced telogen effluvium 5. Trichoscopy (dermoscopic examination of the scalp) may reveal an increased proportion of vellus hairs and empty follicular ostia without the "exclamation-point" hairs that characterize alopecia areata 8.

The American Academy of Dermatology's 2022 practice guidelines recommend documenting at least two of the following before attributing alopecia to a medication: "onset within a plausible pharmacological window, absence of alternative etiologies on standard laboratory screening, and improvement after dose reduction or discontinuation" 13.

What to Do If You Suspect Metoprolol Is Causing Hair Loss

Do not stop metoprolol abruptly. Beta-blocker withdrawal can cause rebound tachycardia, hypertensive urgency, and in patients with coronary artery disease, angina or myocardial ischemia 14. Any change must be supervised by your prescribing physician.

The standard approach involves three steps. First, your doctor will rule out other causes with the lab panel described above. Second, if metoprolol is the likely culprit, a gradual taper over 1 to 2 weeks precedes a switch to an alternative antihypertensive. Third, the replacement drug is chosen based on the original indication (hypertension, heart failure, rate control) 14.

For hypertension alone, ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), and calcium channel blockers (amlodipine) are first-line options that do not carry a class-level association with telogen effluvium 15. For heart failure with reduced ejection fraction, the switch is more constrained because beta-blockers are a pillar of guideline-directed medical therapy. In those cases, carvedilol or bisoprolol may be trialed as alternatives, though all beta-blockers share the theoretical mechanism 16. Nebivolol, a highly selective beta-1 blocker with nitric-oxide-mediated vasodilation, has fewer dermatologic adverse-event reports in VigiBase, making it a reasonable within-class substitution 2.

Supportive Measures During Recovery

While waiting for regrowth, several evidence-based interventions can support follicular recovery. Topical minoxidil 5% applied once daily to the scalp shortens the telogen phase and has been shown to increase hair density by 18.6 hairs/cm² over 24 weeks in women with diffuse thinning 17.

Correct any nutritional gaps. Oral ferrous sulfate 325 mg daily (if ferritin is below 30 ng/mL) and zinc gluconate 50 mg daily (if serum zinc is below 70 mcg/dL) have each demonstrated reduced shedding in controlled trials 9. Biotin supplementation is popular but weakly supported; a 2017 systematic review found no randomized trials proving biotin efficacy for telogen effluvium in biotin-replete individuals 18.

Avoid heat styling, tight ponytails, and chemical treatments during the recovery window. Mechanical traction on weakened follicles can convert reversible telogen effluvium into traction alopecia, which is harder to reverse 8.

Other Beta-Blockers and Hair Loss Risk

Metoprolol is not unique. All beta-blockers carry this class effect, but the magnitude differs. Propranolol, a non-selective beta-blocker, generates more alopecia reports per million prescriptions than any other agent in the class 2. Atenolol, another cardioselective agent, has a reporting rate similar to metoprolol. Nebivolol and bisoprolol appear to have lower rates, though direct comparative trials are absent.

Dr. Lynne Goldberg, director of the Hair Clinic at Boston Medical Center, has noted: "I generally consider nebivolol first when a patient needs to stay on a beta-blocker but is distressed by hair shedding. The pharmacovigilance signal is weaker, and in my clinical experience, patients tolerate the switch well" 10.

The table below summarizes relative risk signals from VigiBase pharmacovigilance data 2:

| Beta-Blocker | Selectivity | Alopecia Reporting Odds Ratio | |---|---|---| | Propranolol | Non-selective | 2.8 | | Metoprolol | Beta-1 selective | 2.1 | | Atenolol | Beta-1 selective | 1.9 | | Bisoprolol | Beta-1 selective | 1.4 | | Nebivolol | Beta-1 selective | 1.1 |

When Hair Loss From Metoprolol Might Be Permanent

True permanent loss from metoprolol alone is rare. The scenario where recovery stalls involves overlapping pathology. A patient with underlying androgenetic alopecia, chronic iron deficiency, and subclinical hypothyroidism who also takes metoprolol may experience follicular miniaturization that does not fully reverse even after drug withdrawal 8.

Scalp biopsy can distinguish between reversible telogen effluvium (increased telogen:anagen ratio with preserved follicle size) and concurrent miniaturization (reduced terminal-to-vellus ratio below 4:1) 12. If miniaturization is present, treatment with finasteride (men) or spironolactone (women) may be warranted in addition to discontinuing the beta-blocker 5.

Patients who have been on metoprolol for more than 5 years with continuous shedding should request a biopsy. Chronic telogen effluvium lasting beyond 6 months after drug removal warrants specialist referral to rule out cicatricial (scarring) alopecia, which requires a different treatment protocol entirely 13.